La cadena de opciones muestra datos clave de las opciones de acciones de Emergent BioSolutions a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Emergent BioSolutions..

Emergent BioSolutions (NYSE:EBS) Bolsa, Cadena de Opciones

EMERGENT BIOSOLUTIONS INC

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal&nbsp;Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in vivo data, including human case studies of the investigational use of brincidofovir, the current evaluation for treating mpox infections in adults and pediatrics in the Democratic Republic of Congo, and the potential for combination therapy with tecovirimat for immunocompromised patients with severe disease.&nbsp; &nbsp;&nbsp;

Biotech

News

General

Emergent BioSolutions Publishes Comprehensive Review On Brincidofovir For Mpox In 'Expert Review of Anti-infective Therapy' Journal

Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this public health issue a priority.
Expanding access to potentially life-saving treatments is critical to saving more Americans and their families from an opioid overdose death. Emergent remains focused on saving lives through efforts to increase access, awareness and the availability of NARCAN&#xAE; Nasal Spray 4 mg and KLOXXADO&#xAE; Nasal Spray 8 mg. Emergent strives to engage with key stakeholders committed to reducing overdose deaths, as one death is one too many.
"The efforts of Representative Carter (R-GA) to make naloxone readily available in the U.S. House of Representatives are commendable, and we are pleased to recognize his work to help save a life during an opioid overdose emergency," said Joe Papa, president and chief executive officer at Emergent. "We believe the over-the-counter availability of naloxone, including our product, NARCAN&#xAE; Nasal Spray, has directly contributed to the reduction in overdose deaths reported by the U.S. Centers for Disease Control and Prevention. Measures like this reinforce the importance of having life-saving naloxone nearby as an opioid overdose can happen to anyone, anywhere and at any time."
In 2023, Emergent launched NARCAN&#xAE; Nasal Spray as the first OTC opioid overdose reversal treatment. With more than 85 million doses distributed in the U.S. and Canada since 2016, it is an important tool in helping save lives from opioid overdose, including those caused by fentanyl. Emergent is the leading U.S. supplier of nasal naloxone, and offers an expanded range of products to support public interest groups, workplaces/businesses, as well as patients, consumers and healthcare providers. &nbsp;
<ul>
<li>NARCAN&#xAE; (naloxone HCl) Nasal Spray 4 mg (two-dose carton)</li>
<li>NARCAN&#xAE; Nasal Spray Wall Unit Kit: includes wall unit cabinet with alarm, poster and wayfinder sign</li>
<li>KLOXXADO&#xAE; (naloxone HCl) Nasal Spray 8 mg (two-dose carton)</li>
<li>Convenience Kits: includes medical grade components including: One hard case with internal pockets, one medical grade CPR mask, one pair of nitrile examination gloves</li>
</ul>
Visit <a href="https://www.globenewswire.com/Tracker?data=Zp6B7jyyWVCT8FLVmW9BnKhVyKGNgGGE8LZSvwkL239_KSPsnCI4dXycrGVwNw98FBjxwbsALmq3ZfBRunCVpFX1s6MSbkm4X7ShNTT6tpY=">NARCANDirect&#xAE;</a> or one of Emergent's product sites, <a href="https://www.globenewswire.com/Tracker?data=zmN-_d91pMgn_kvpjdRlbZ9KiY7wB76ibIy7mj0g2BYC4e2LCQ5ol0ovTBqwDH7QOrx8E2ndbgruIIbJwkyzCfI0BAgJNlLS9OGmeo6tRjwRwMnsKzCuZWDKUOtlqiw3uyM3uf_0dchEd-iIpkzba2Ydp4AsukR_Z5D2yZSWJ1Zbw6mW4fmLYmxxr8xy0CAAIfuyOp30NqRoC5-3v-dyLACzSr-e_qTuRrMZD0Z9fRI07QDUxN4XlKMUpzj6uW_mUk9GfpV-06dLLd-CvfV04v8mI747CLdCBEfgQYRLmfmupzKNlmSJLRjHf8CHEKITrxNE4oS7QO_F28ZWCjNRlvev832dxPSHbmNiiHnMBmDPEnN1XhYUXkRW-I6hLPPjBJYJFQ1K1vz-0OIFKPzLv3CMocZY0iR1XYffFe86poij4mAQPW3g3j-exJlxiRYOvOqR1TCAkX5GP3a7IrvWi2MgWDMRdOAOQ2bN4ubX156gHVTeF2Mp35xoePS8KIPD0SUryFeYKoBiF0VcLtXpCQBielinpzXnvy3RpJr5Q-Ge3bV39j4NaXNr3dP2fplyP9Rlt8lD7-DbTF28BgcLrDBdA3aeqK2Tke0nSLIofI-JTDxtE7B21ovbOEUkEwR0vdlJ3x4Up9nO-5wccqZln4g1P8gDVqmM82MddBzS_AeDnZrHrWtbPkfNqd9YrtgTvx_fHKfAVnJ9-EJxA_CNxYtj-Q3hGmDsAnN_rzRDOPbMh-5GOaSwB3DZGWZzRGM8">KLOXXADO.com</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Zp6B7jyyWVCT8FLVmW9BnPTgcQ9142ffOzM-PjRbHXCcAMUegrLoy5OEgTthSa7VZtHcjV5JYzez-FxckB2ajJVJcN-ESdcW7as2-6hfMZdklchA5O-AxohrULFeFbJhoFtwdXW5L3upMGszdzZ_SIHtnOQbDTVSkD86vCslIFtYXbc4-zrp2e0K_HyUnVIHkPabPCS4JbDrNaRrOB_T4hZu2OG1poW14CHqiZ_HF0BCjWbtLK-0_xRJpKnYYtonQe8zfzImAJpDVOOuPS8bP4osJZTM6MlMTdFadVHnMzt8fCNmg59lK7ZeB_6qkj_BCM21w2SGg8FDKGMkDGXK6kic7vclO2ksOBGt1HqrhmmN_TLcUInnS8E1nvCuWBRyvgLmLKsc_J-om5Kb7TjhfD1GS-zuQyI2-8c6uqJbexSl4nZ3JEQjR_83urQcRXqH3JTt3Usa89V-cFXXy3KY9L141fmR5ghafAAS9HAykJaf7xrb75aYRtN82pYrXYJ9aM0NlllpjIaPZFLvP3lVQTXdYmmFGM_psfoD0PHuaoSNLgFgRil9DeGYPILDY7B2o_fEDqwoUw6M_7Eiiv-Lp5aGyG0R7eLykaF355kFBwvtYf3FGufDjgD3w5qHB5eykhw3t_6ebQZcJZc36dXbT9FF_CcV3i6jcgyfj-HMsv7BVQUcc76HSMfHqDYghdLGpZPoLFc9RkGeDfRYBCJ593HN9P9L5R6LQ2lMuCIBTd3XafhCwP7wRiKyR3yTbRdw">NARCAN.com</a>&nbsp;to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone.

Emergent BioSolutions Applauds U.S. House For Adding OTC Naloxone To AED Locations To Combat Opioid Overdose Deaths

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced a contract modification has been secured to deliver CNJ-016&#xAE; [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the&nbsp;U. S. Department of Health and Human Services&nbsp;(HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
"Securing this contract modification for VIGIV treatment underscores Emergent's ongoing partnership with the U.S. government to support its overall smallpox preparedness strategy," said&nbsp;Paul Williams, senior vice president, head of products business, global government &amp; public affairs at Emergent. "We are proud to fulfill our mission to protect and save lives and stand ready to provide our diverse medical countermeasures through our North American supply chain and capabilities for stockpiling to help address public health threats in the United States and around the world."
This contract modification award follows Emergent's <a href="https://www.globenewswire.com/Tracker?data=tqV7WeBrifAVd4KM0bsoSSbaTqcNDJYiZpbwNAHN6wFUuYRe3yliUPDM5UXQpMHbNM9jp-WL0eGwdtRHz1r6FTSapLMOGa508dA4n-zKUQ4bes6i3Dq2twzP9XUm75NAKJ5nGJCHUbftDtqioJfgl3E5CP7i9d_YJvc3vo03g6F0wtRO71wVYCDy7C3oYKD0Om_Zpn7g3r9wO7OQ1q9M09YlVS7Eg8rm8X93c9lbo_i8kKRcN69N-QQxfxCrrjNY">recently announced</a> BAT&#xAE;&nbsp;[Botulism Antitoxin Heptavalent (A, B,&nbsp;C, D, E,&nbsp;F, G) – (Equine)] contract amendment with ASPR under contract 75A50119C00075.

Contracts

Emergent BioSolutions Wins $51.9M Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] As Part oO U.S. Biodefense Preparedness Efforts

GAITHERSBURG, Md., July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced the expansion of its proprietary NARCANDirect&#xAE;&nbsp;online distribution network to include KLOXXADO&#xAE;&nbsp;(naloxone HCl) Nasal Spray 8 mg. The platform provides qualified direct purchasers, including emergency medical services, law enforcement, fire departments, government agencies, schools/universities and community-based naloxone distribution programs with streamlined access to opioid overdose response products. This addition complements the existing availability of NARCAN&#xAE;&nbsp;(naloxone HCl) Nasal Spray 4 mg, increasing access to naloxone across the United States.
In January 2025, Emergent <a href="https://www.globenewswire.com/Tracker?data=6rwHUtMWSXWNe_lnsvZy4V9H3h8bp4ebCHGHSJWMcv4ZA3XgxFLfycOCJujwrmfSBCZy9wmul7iRxyXGpZhxFLEcXevxvY0tJBb9dZfL27zEyBDLVAIR4i81YBDQdRN0ggJbcQR11DbLE1hcKF9uK-w1g2GvlErdz53_OZSAtixV38RD9CKt99EXFRz7RhndX4CFoaJd8g5rfc4mZ4nmdEQ6EMhkMpBadZdelFryY0zqd_ZRJO7SwGLgaC90JWJp6urhyOrB4C6cMt303C0ezHMivnk2ENPmacCKf_32ToI=">acquired exclusive commercial rights to KLOXXADO&#xAE;</a>&nbsp;Nasal Spray in the U.S. and Canada in an effort to help save lives by increasing access and availability of life-saving naloxone. By distributing both NARCAN&#xAE;&nbsp;Nasal Spray 4 mg and KLOXXADO&#xAE; Nasal Spray 8 mg through Emergent's expansive distribution networks, key stakeholders and communities now have more options in responding to opioid emergencies. KLOXXADO&#xAE;&nbsp;Nasal Spray is a higher dose prescription emergency treatment for a known or suspected opioid overdose. NARCAN&#xAE;&nbsp;Nasal Spray is available across the U.S and Canada and continues to be a trusted 4 mg naloxone standard of care in the community setting.
Expanding naloxone tools through NARCANDirect&#xAE;&nbsp;comes at a pivotal moment in the ongoing fight against the opioid epidemic as provisional data released in May from the Centers for Disease Control and Prevention (CDC) show that drug overdose deaths in 2024 decreased 27 percent, with opioid-related deaths dropping by 34 percent from 2023.1 Shortly after this initial report, the CDC reported new provisional data available as of June 1, 2025 that found overdose deaths increased by roughly 1,400 in a 12-month period from January 2024 to January 2025.2,3 This incremental increase demonstrates the persistent and evolving nature of the opioid crisis, further reinforcing the continued need for new tools and ongoing support to ensure widespread opioid emergency preparedness.
"Tremendous progress in the fight against the opioid epidemic has been made since NARCAN&#xAE;&nbsp;Nasal Spray became available over the counter in 2023, but this most recent uptick in overdose deaths reaffirms that we cannot simply stay the course," says Paul Williams, senior vice president, head of products business, global government &amp; public affairs at Emergent. "Adding KLOXXADO&#xAE; to our NARCANDirect&#xAE;&nbsp;distribution is an important step in broadening access to naloxone and saving more lives. We will continue to work with partners across sectors to adopt new approaches and make systemic changes to ensure businesses, communities and individuals nationwide are ready to rescue."
Emergent is also introducing Convenience Kits on NARCANDirect&#xAE;, which will equip frontline responders and community programs with the requested components of one medical-grade CPR mask and one pair of nitrile examination gloves for overdose response, provided in a durable hard case with internal pockets. To access these new offerings, public interest customers should visit <a href="https://www.globenewswire.com/Tracker?data=nVvlMFUtzi-ABVhdclFWEj9HvvBgqzPPmVDwolIZXy9LngzoQVQZSH_Sk3Z9EY9BKXaDHoGMpVZ4Z5S7Z2x860nAuJrsyTfJmKxb0xJV8s4=">NARCANDirect.com</a>. Consumers, patients and healthcare providers can visit <a href="https://www.globenewswire.com/Tracker?data=gwY_fsyscvq-iHwoQJL4u5kItIgAZkIvLMlV1BJWWYXpyJj7tTJ60OUIMVUvXsCTC_pxL2TeLDTiIZAsPi45Fw==">KLOXXADO.com</a> and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=nVvlMFUtzi-ABVhdclFWEiKaFGZaQuDi4P3ewoH4Hx1d971ye12cWLiRod9vDwtcyYXAfztpFfh2zYyrIXm7Rw==">NARCAN.com</a> to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone.

Emergent BioSolutions Expands Its Proprietary NARCAN Direct Online Distribution Network To Include KLOXXADO Nasal Spray 8 Mg

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the&nbsp;United States Department of Health and Human Services&nbsp;(HHS) for BAT&#xAE; [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT&#xAE;, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.

Emergent Biosolutions Bags $62.4M Contract Modification From United States Department Of HHS' ASPR For BAT

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) shares moved upwards by 176.1% to $3.92 during Friday's pre-market session. The market value of their outstanding shares is at $251.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock increased by 28.78% to $0.25. The company's market cap stands at $7.2 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) stock increased by 21.46% to $4.3. The market value of their outstanding shares is at $80.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) stock moved upwards by 13.81% to $2.06. The company's market cap stands at $104.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 12.34% to $6.17. The company's market cap stands at $334.7 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock increased by 11.55% to $25.77. The market value of their outstanding shares is at $165.8 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 65.7% to $0.01 during Friday's pre-market session. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares declined by 19.53% to $47.04. The market value of their outstanding shares is at $8.7 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock declined by 17.26% to $17.5. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 13.85% to $2.23. The market value of their outstanding shares is at $13.7 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 13.08% to $0.3. The market value of their outstanding shares is at $7.6 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares decreased by 12.0% to $3.52. The market value of their outstanding shares is at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AYTU

CABA

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DOCS

HCTI

INZY

KLRS

KLTO

SNSE

TNXP

TVTX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) stock rose 18.2% to $2.14 during Thursday's after-market session. The company's market cap stands at $104.5 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock increased by 13.8% to $0.41. The market value of their outstanding shares is at $10.4 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 13.34% to $6.2. The company's market cap stands at $4.1 million. The company's, Q1 earnings came out today. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock rose 12.02% to $6.15. The market value of their outstanding shares is at $333.8 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 9.36% to $1.81. The company's market cap stands at $2.6 million. </li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) stock rose 9.22% to $5.09. The company's market cap stands at $83.4 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 69.4% to $0.01 during Thursday's after-market session. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares decreased by 24.74% to $43.99. The company's market cap stands at $8.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock fell 24.32% to $16.0. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares declined by 10.98% to $0.24. The company's market cap stands at $12.3 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares declined by 8.99% to $2.33. The market value of their outstanding shares is at $477.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) stock declined by 8.05% to $1.6. The market value of their outstanding shares is at $19.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAGX

MHUA

QTTB

SRTS

TSHA

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares rose 39.1% to $35.96 during Thursday's regular session. The company's market cap stands at $2.4 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 38.08% to $6.54. The company's market cap stands at $355.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock increased by 32.83% to $15.6. The company's market cap stands at $276.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) stock increased by 24.11% to $14.41. The market value of their outstanding shares is at $481.3 million. As per the press release, Q1 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock moved upwards by 22.84% to $2.85. The market value of their outstanding shares is at $107.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock increased by 21.64% to $6.88. The company's market cap stands at $343.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 74.5% to $0.12 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 69.32% to $0.16. The company's market cap stands at $20.5 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock decreased by 64.04% to $0.11. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 43.31% to $0.23. The market value of their outstanding shares is at $11.8 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) stock fell 29.1% to $1.17. The market value of their outstanding shares is at $25.3 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares fell 28.83% to $3.44. The market value of their outstanding shares is at $123.9 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVB

AXDX

CYRX

DCTH

GNLX

NCNA

QDEL

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Emergent BioSolutions shares are trading higher after the company reported better-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 22.9% to $0.44 during Thursday's pre-market session. The market value of their outstanding shares is at $27.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 18.55% to $5.62. The market value of their outstanding shares is at $305.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock rose 16.37% to $1.35. The market value of their outstanding shares is at $22.3 million. </li>
<li>Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) shares moved upwards by 16.18% to $5.6. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock moved upwards by 12.94% to $6.72. The company's market cap stands at $1.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares increased by 12.6% to $2.77. The company's market cap stands at $723.6 million. As per the press release, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 63.4% to $0.11 during Thursday's pre-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 29.2% to $0.33. The company's market cap stands at $8.2 million. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) shares fell 14.69% to $5.81. The market value of their outstanding shares is at $41.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares decreased by 13.47% to $5.91. The market value of their outstanding shares is at $106.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 13.32% to $0.59. The market value of their outstanding shares is at $2.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 12.5% to $0.01. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

AVAH

CGTX

ECOR

LGMK

MIRA

NVAX

ZVSA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares increased by 17.4% to $9.32 during Wednesday's after-market session. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q1 earnings came out today. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) stock increased by 15.38% to $0.45. The company's market cap stands at $30.1 million. As per the press release, Q1 earnings came out today. </li>
<li>Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) stock increased by 12.9% to $42.52. The company's market cap stands at $7.9 billion. The company's, Q1 earnings came out today. </li>
<li>GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) stock increased by 8.97% to $4.13. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q1 earnings came out today. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares increased by 8.79% to $0.23. The company's market cap stands at $9.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 8.43% to $5.14. The company's market cap stands at $279.2 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 70.2% to $0.09 during Wednesday's after-market session. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) stock decreased by 14.08% to $5.85. The market value of their outstanding shares is at $42.0 million. The company's, Q1 earnings came out today. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock fell 13.98% to $0.01. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) stock declined by 13.47% to $5.91. The company's market cap stands at $105.7 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) stock decreased by 12.04% to $17.1. The company's market cap stands at $846.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares fell 10.18% to $0.66. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVO

CARM

GBIO

GDRX

RVMD

STAA

12 Health Care Stocks Moving In Wednesday's After-Market Session

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) affirms FY2025 sales outlook from $750.00 million-$850.00 million to $750.00 million-$850.00 million vs $819.33 million estimate.

Guidance

Emergent BioSolutions Affirms FY2025 Sales Guidance of $750.00M-$850.00M vs $819.33M Est

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.44 by 61.36 percent. This is a 20.34 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $222.20 million which beat the analyst consensus estimate of $219.00 million by 1.46 percent. This is a 26.03 percent decrease over sales of $300.40 million the same period last year.

Earnings

Earnings Beats

Emergent BioSolutions Q1 Adj. EPS $0.71 Beats $0.44 Estimate, Sales $222.20M Beat $219.00M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

Earnings Scheduled For May 7, 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target

Buybacks

Emergent BioSolutions Approves $50M Shares Buyback On Or Before March 27, 2026

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Emergent BioSolutions and provided 12-month price targets. The average target is $15.0, accompanied by a high estimate of $15.00 and a low estimate of $15.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1742562027_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Emergent BioSolutions among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Emergent BioSolutions. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emergent BioSolutions compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Emergent BioSolutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Emergent BioSolutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EBS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Emergent BioSolutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Emergent BioSolutions Better</h2>
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
<h3>Emergent BioSolutions's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Emergent BioSolutions's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -29.86% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Emergent BioSolutions's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -16.53%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Emergent BioSolutions's ROE stands out, surpassing industry averages. With an impressive ROE of -6.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.18%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 1.37, Emergent BioSolutions faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts

Hikma Announces Health Canada Approval Of KLOXXADO Nasal Spray; To Be Marketed, Sold By Emergent BioSolutions Under 6-Year Commercial Agreement

Asset Sales

Emergent BioSolutions Finalizes Baltimore-Bayview Manufacturing Site Sale To Syngene International; Emergent Receive ~$36.5M

Press Releases

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Emergent BioSolutions Announces Addition to Russell 3000® Index

Health Care

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Comments

Emergent BioSolutions

Emergent BioSolutions (EBS) Opciones

Emergent BioSolutions (NYSE:EBS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL